Emerging immunotherapy using anti-PD-1 antibodies have improved survival in cancer patients by immune activation. Here we show that functional PD-1 receptor is present in hippocampal CA1 neurons and loss of PD-1 or local anti-PD-1 treatment with nivolumab enhances neuronal excitability and long-term potentiation in CA1 neurons, leading to enhanced learning and memory. Our findings suggest that anti-PD-1 antibody also acts as a neurotherapy for improving memory and counteracting cognitive decline.
, indicating increased capability of new object learning. Water maze test further revealed that the latency to locate the platform was shorter in KO mice (P<0.001, Fig. 1b, Supplementary   Fig. 1b ) and the number of crossing was enhanced in KO mice (P<0.01, vs. WT, Fig. 1c ). Thus, loss of PD-1 can enhance learning and memory in naïve mice without neurodegeneration.
To circumvent developmental compensation in Pd1 −/− mice, we examined whether central PD-1 blockade in WT mice could recapitulate the phenotypes observed in KO mice. Nivolumab is a FDA-approved fully humanized IgG4 monoclonal antibody and binds mouse PD-1 to produce functional blockade in behavioral assays in mice 7 . Intraventricular (ICV) administration of nivolumab at a very low dose (1 g ≈ 7 pmol, 3 x 1 g, every other day) significantly enhanced new object learning, as compared to human IgG4 control (P<0.01, Fig. 1d ). ICV administration of nivolumab (5 x 1 g, every other day) also enhanced memory in the water maze test (P<0.05, vs.
control IgG4, Fig. 1e,f) . Notably, swimming speed was slightly increased after Pd1 deletion but not after nivolumab treatment ( Supplementary Fig. 1c, d ), suggesting that memory improvement is not a result of enhanced swimming capability.
Next, we investigated learning and memory in 10 month-old WT and KO mice. Compared with young adult mice (2-3 months), 10 month-old WT mice showed decreased discrimination index (45% vs. -4%, P<0.05, Fig. 1d, g, Supplementary Fig. 1e ), indicating age-related cognitive decline in mice. However, 10 month-old KO mice had significant higher learning index (P<0.05 vs. WT old mice, Fig. 1g ). 10 month-old WT mice also showed declined memory capacity in water maze test (P=0.0546, vs. young mice, Supplementary Fig. 1f ). Strikingly, 10 month-old-KO mice were protected from memory deterioration, showing significantly shorter latency to locate the platform (P<0.01 vs. old-WT mice, Fig. 1h, i) . Memory was almost intact in 10 month-old-KO mice when compared to young-KO mice (latency: 12 s in 10 month-old-KO mice vs. 9s in young-KO mice, Fig. 1c, i, and Supplementary Fig. 1f) . Notably, the swimming speed between 10 month-old WT and KO mice was comparable ( Fig. 1i, left) . Taken together, these data suggest that PD-1 is an endogenous inhibitor of learning and memory in both young and 10 month-old mice.
Hippocampal CA1 neurons play critical roles in learning and memory 9, 10 . To define neuronal mechanisms by which PD-1 regulates learning and memory, we examined neuronal excitability in CA1 neurons using brain slice preparation. Patch-clamp recordings showed that Pd1deficient neurons had increased resting membrane potential (RMP, P<0.05, WT vs. KO, Fig. 2a ). Fig. 2a ) but fired more action potentials (AP) following a ramp of 0-130 pA current injection (P<0.0001, WT vs. KO, Fig. 2b, Supplementary Fig. 2b) . Intriguingly, spontaneous discharges was found in 40% of Pd1-deficient CA1 neurons (8/20) but none were observed in 20 WT neurons ( Fig. 2c) .
Pd1-deficient neurons showed no changes in AP amplitude and duration (Supplementary
Thus, loss of PD-1 results in an increase in neuronal excitability in CA1 neurons. Strikingly, this increase was also found in WT mice following anti-PD-1 treatment. Acute treatment of brain slices with nivolumab (7 nM, 2 h) did not change RMP but significantly increased AP number (P<0.01, Fig. 2d, e ) and AP frequency (P<0.05, Supplementary Fig. 2c ) in CA1 neurons. These findings suggest a cell-autonomous PD-1 signaling mechanism within hippocampal neurons.
We then examined PD-1 expression and found that hippocampal neurons express PD-1 protein or Pd1 mRNA. Double staining revealed that PD-1 is expressed by CA1 neurons that coexpress the neuronal marker NeuN (Fig. 2f) . The PD-1 staining was abolished by the blocking peptide 7 and lost in Pd1-KO mice ( Supplementary Fig. 3b,c) . PD-1 was expressed by 20-40% CA1 and CA3 neurons (Extended Data Fig. 3a, d) . Consistently, in situ hybridization revealed Pd1 mRNA expression in CA1 and CA3 (Supplementary Fig. 3e ). Immunocytochemistry in cultured hippocampal neurons also showed PD-1 expression in cytoplasm/surface ( Fig. 2g) .
To rule out the contribution of surrounding cells to the electrical activities recorded in the CA1 neurons, we also examined neuronal excitability in dissociated hippocampal neurons in primary cultures from E17-E19 mice. Compared to WT neurons (7-8 days in vitro, DIV), Pd1deficient primary neurons (DIV 7-8) had a moderate increase in RMP (P=0.0729, Fig. 2h ) but fired more AP following a ramp of current injection (P=0.0002, Fig. 2i ). Notably, 39% (7/18) of Pd1deficient neurons exhibited spontaneous discharges, while only 12.5% (2/16) WT neurons exhibited spontaneous discharges ( Fig. 2j) . Thus, CA1 neuron-intrinsic PD-1 is sufficient to regulate neuronal excitability.
We next examined synaptic transmission and plasticity in CA1 neurons in brain slices with PD-1 deletion or blockade. We found marked increases in the frequency (P<0.0001) and amplitude (P<0.05) of miniature EPSCs (mEPSCs) in CA1 neurons of KO mice ( Fig. 3a, b ). PD-1 blockade with nivolumab (7 nM, 2 h) in WT slices also increased mEPSC frequency (P<0.05, Fig. 3c, d) .
As an important form of synaptic plasticity underlying learning and memory 11 , long-term potentiation (LTP) in CA1 neurons could be induced by high frequency electrical stimulation of Schaffer collaterals in brain slices ( Fig. 3e, f) . Interestingly, this form of LTP was greatly enhanced 5 in Pd1-deficient (P<0.01, vs. WT slices, Fig. 3e ) as well as in WT brain slices treated with nivolumab (7 nM, 2 h, P<0.05, vs. IgG control, Fig. 3f ).
LTP is also associated with dendritic morphological changes 12 . Loss of PD-1 resulted in increased dendritic spine density in CA1 neurons of KO mice (P<0.01, Fig. 3g, h) , without affecting neuronal survival in the hippocampus (Supplementary Fig. 4 ). In agreement with the result from KO mice, anti-PD1 treatment in WT slices with nivolumab (7 nM, 2 h) also increased spine density (P<0.05, Fig. 3i, j) . The size of spines did not change after Pd1 deletion or PD-1 blockade ( Fig. 3g-h) .
In summary, our findings have demonstrated a previously unrecognized role of neuronal PD-1 in regulating learning and memory. Previous studies showed that systemic anti-PD-1 treatment enhanced memory in mouse AD models, as a results of recruitment of immune cells (e.g., macrophages) and subsequent clearance of amyloid- plaques 3, 4 . Contradictory results were also reported 5, 6 . We previously demonstrated the presence of functional PD-1 in peripheral sensory neurons which regulates nociceptor excitability and pain 7 . In this study, we demonstrated that functional PD-1 is present in CNS hippocampal neurons and PD-1 serves as an endogenous inhibitor of learning and memory via a direct modulation of neuronal excitability and synaptic transmission. Thus, PD-1 is a neuronal inhibitor both in the PNS and CNS. Inhibition of PD-1 could enhance learning and memory in young mice and 10 month-old mice with age-related cognitive decline. Mechanistically, anti-PD-1 treatment potentiates learning and memory by enhancing neuronal excitability, synaptic transmission, and synaptic plasticity (LTP) and increasing dendritic spines in CA1 neurons. Our findings suggest that anti-PD-1 treatment, a magic bullet for immunotherapy, may also be used as a neurotherapy for enhancing learning and memory.
Future studies are warranted to test whether anti-PD1 treatment enhances memory in AD and dementia patients via both immune-and neuro-therapies.
METHODS
Methods are available in the online version of the paper.
Note: Supplementary Information is also available in the online version of the paper. for c-f. Data were expressed as mean ± s.e.m. Supplementary Fig.1 Context prehabituation Sample sizes were estimated based on our previous studies for similar types of behavioral, biochemical, and electrophysiological analyses [13] [14] [15] . Animals were randomly assigned to each experimental group. Two to five mice were housed in each cage. All behavioral measurements were conducted in a blinded manner and during daytime (light cycle) normally starting at 9 AM.
Animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The number of animals and sample size of each experiment was also described in Supplementary Table 1 .
Reagents, stereotaxic surgery and drug delivery. Human IgG4 (Catalog: ab90286) were purchased from Abcam. Nivolumab (OPDIVO®), a humanized anti-PD-1 antibody, was purchased from Bristol-Myers Squibb. For stereotaxic surgery, mice were anesthetized with isoflurane (4% for induction and 2% thereafter for maintenance), and their heads were fixed in a stereotaxic apparatus (Narishige scientific instrument lab.). A guide cannula (62004, RWD Life Science) was stereotaxically implanted into the left lateral ventricles (AP: -0.3 mm; ML: +1.3 mm; V: -2.0 mm) based on the mouse brain atlas 16 . After four-day recovery, an infusion needle (62204, RWD Life Science) was inserted into lateral ventricles through the guide cannula to a depth of 2.5 mm for drug injection. Following the completion of the infusion, the needle was left for an additional 2 min to limit reflux.
Novel object recognition test. On the first day, mice were placed in a 30 × 30 × 30 cm square arena (TAP plastics) for habituation. On the second day, two identical objects were placed in two distinct corners of the arena. Then, the mice were returned to its home cage for a 0.5-h or 24-h retention interval, and one of two identical objects was replaced by a new object for novel object recognition test 17 . After the retention interval, animals were placed back into the testing arena for 5-min exploration. A valid exploration was defined as mouse touching an object with nose or focusing attention toward the object at a distance of <1 cm. Turning around, climbing, and siting on the object were all considered to be invalid. A discrimination index was used to evaluate the scores of exploration time for the familiar or novel object (N -F/N + F) ×100%. Animal behaviors were video-recorded and analyzed by an experimenter who was blind to the testing conditions. Data were excluded if the total exploration time is less than 10 s.
Morris water maze test. The Morris water maze test was conducted in a circular pool (diameter 120 cm) filled with 40 cm-height water maintained at room temperature (23 ± 1°C). The water was made opaque with white milk powder. The pool is located in an experimental room with many visual cues and divided into four equal quadrants. A circular platform, 10 cm in diameter, is placed in the middle of one fixed quadrant of the pool, just 1 cm underneath the water surface. During the training process, mice were trained for four trials each day for four consecutive days. In the probe test (day 5), the platform was removed and all mice were given one probe trial for 60 s searching 18 .
The swimming speed, latency to platform zone and number of platform zone crossing were automatically recorded by ANY-maze (Stoelting Co.).
Brain hippocampal slices preparation. Five to eight weeks old mice were anesthetized and then decapitated. The brain was quickly transferred to ice-cold artificial sucrose-based cerebrospinal (GIBCO). Hippocampi were mechanically dissociated using fire-polished pipettes, filtered through a 100-µm nylon mesh and centrifuged (1,000 g for 5 min). The pellet was resuspended and plated on poly-D-Lysine/Laminin coated glass coverslips (CORNING), and cells were plated in DMEM containing 5% fetal bovine serum, 1% penicillin and streptomycin. After 5-6 h, primary cultures were switched to Neurobasal Plus medium containing 2% B27 supplement, 1% GlutaMAX-I, 1%
penicillin and streptomycin (GIBCO). Three days after plating, cytosine arabinoside was added to a final concentration of 10 µM to curb glial proliferation. Whole-cell recoding and immunostaining experiments were conducted on DIV 7-8. 
Whole

